ReShape Lifesciences Inc. (RSLS)

0.1224 -0.0087 (-6.636%)

IEX Real-Time Price

August 14, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 0.1311

Price Open 0.155

Volume: 37.41M

Avg Volume: 6.23M

Market Cap: 861,005

P/E Ratio -0.04

52 Wk Range 0.05-39



RSLS Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
5.31M
381,259
0.43
7.18%

2018-07-13
3.91M
534,928
0.56
13.66%

2018-06-29
3.91M
192,863
0.66
4.93%

2018-06-15
1.8M
207,802
1.57
11.57%




RSLS Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-15
Q1 2018
N/A
0.00 (0)
-0.56
0.00

2018-05-14
Q1 2018
AMC
0.00 (0)
-0.36
0.00

2018-04-02
Q4 2017
AMC
0.00 (0)
-0.56
0.00

2018-03-22
Q4 2017
AMC
0.00 (0)
-0.56
0.00

News

ReShape Lifesciences EPS of -$14.23 (2018-08-14 17:21 SeekingAlpha)

ReShape Lifesciences (NASDAQ: RSLS ): Q2 EPS of -$14.23 may not be comparable to consensus of -$1.79. Revenue of $0.65M (+550.0% Y/Y) misses by $0.37M . Shares -15% AH. Press Release More news on: ReShape Lifesciences Inc., Earnings news and commentary, Healthcare stocks news, ,…

 


Statistics

Shares Outstanding: 6.38M

Top 15 Institution Percent: 12.70

Price To Sales: 0.44

Price To Book: 0.01

Revenue: 453080

Gross Profit: 184097

Cash: 34.63M

Debt: N/A

Return On Assets: -75.16

Return On Equity: -89.92

Profit Margin: N/A

Price History

Beta: 2.43

50-day Moving Avg: 1.91

200-day Moving Avg: 14.32

YTD Change: -99.48

5-day Change: 85.17

1-month Change: -91.95

3-month Change: -98.33

6-month Change: -99.42

1-year Change: -99.58

Revenue Per Share: 0.00

Revenue Per Employee: 5459.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: ReShape Lifesciences Inc.

Exchange: NASDAQ Capital Market

Industry: Medical Devices

Sector: Healthcare

Website: https://www.reshapelifesciences.com

Reshape Lifesciences Inc is a medical device company. The company is focused on the design and development of devices which use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders.